Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jacob Moses manages a company patent portfolio that currently features 1 pending office action. This prosecution activity is handled by 1 distinct examiner, showing a concentrated focus for the pending matters. The data indicates that there are 0 distinct art units involved in these specific pending actions. This suggests that the current patenting activity is highly localized within the patent office's organizational structure.
PAK, MICHAEL D is the busiest examiner for this portfolio. This examiner is responsible for 1 pending office action. Because the total count of pending office actions is 1, PAK, MICHAEL D is managing the entire pending workload for Jacob Moses at this time. This singular focus means that all current prosecution results for this portfolio depend on the review of this one examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567712 | CXCR5, PD-1, AND ICOS EXPRESSING TUMOR REACTIVE CD4 T CELLS AND THEIR USE | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567712 | CXCR5, PD-1, AND ICOS EXPRESSING TUMOR REACTIVE CD4 T CELLS AND THEIR USE | PAK, MICHAEL D | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18567712 | CXCR5, PD-1, AND ICOS EXPRESSING TUMOR REACTIVE CD4 T CELLS AND THEIR USE | PAK, MICHAEL D | — | §102§103§112 | Non-Final OA | — | Pending | Dec 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJacob Moses has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Michael D Pak has the most, with 1 of Jacob Moses's pending office actions.